Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William J Gradishar

Showing results (131-140 of 195) with videos related to

Pageof 20
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2025
Molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): using real-world data to describe this unique clinical entityAndrew A Davis, Ellen Jaeger, Ian S Hagemann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2017
Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast CancerGiovanna Rossi, Zhaomei Mu, Alfred W Rademaker, et al.
Breast Cancer Research and Treatment|August 12, 2003
Expedition Inspiration Fund for Breast Cancer Research Meeting 2003Harry Bartelink, Christopher Benz, Don Cleveland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2020
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVEStephen R D Johnston, Roberto Hegg, Seock-Ah Im, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 2, 2006
NCCN Task Force Report: Adjuvant Therapy for Breast CancerRobert W Carlson, Elizabeth Brown, Harold J Burstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2017
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVEStephen R D Johnston, Roberto Hegg, Seock-Ah Im, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectantsMartee L Hensley, Karen L Hagerty, Tarun Kewalramani, et al.
Oncotarget|May 4, 2018
A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancerCesar August Santa-Maria, Taigo Kato, Jae-Hyun Park, et al.
The Journal of Clinical Investigation|November 18, 2025
USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-IKun Liu, Radhika Iyer, Yi Li, et al.
European Journal of Cancer (Oxford, England : 1990)|May 7, 2019
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)Amelia McCartney, Chiara Biagioni, Gaia Schiavon, et al.
Pageof 20

Showing results (131-140 of 195) with videos related to

Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2025
Molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): using real-world data to describe this unique clinical entityAndrew A Davis, Ellen Jaeger, Ian S Hagemann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2017
Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast CancerGiovanna Rossi, Zhaomei Mu, Alfred W Rademaker, et al.
Breast Cancer Research and Treatment|August 12, 2003
Expedition Inspiration Fund for Breast Cancer Research Meeting 2003Harry Bartelink, Christopher Benz, Don Cleveland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2020
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVEStephen R D Johnston, Roberto Hegg, Seock-Ah Im, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 2, 2006
NCCN Task Force Report: Adjuvant Therapy for Breast CancerRobert W Carlson, Elizabeth Brown, Harold J Burstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2017
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVEStephen R D Johnston, Roberto Hegg, Seock-Ah Im, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectantsMartee L Hensley, Karen L Hagerty, Tarun Kewalramani, et al.
Oncotarget|May 4, 2018
A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancerCesar August Santa-Maria, Taigo Kato, Jae-Hyun Park, et al.
The Journal of Clinical Investigation|November 18, 2025
USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-IKun Liu, Radhika Iyer, Yi Li, et al.
European Journal of Cancer (Oxford, England : 1990)|May 7, 2019
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)Amelia McCartney, Chiara Biagioni, Gaia Schiavon, et al.
Pageof 20